Comparison of En Bloc Resection and Intralesional Excision for Re-resection of Giant Cell Tumors of the Spine

Abstract

Objective: Re-resection of spinal giant cell tumors is an exceedingly difficult procedure. Moreover, the prognosis of patients with en bloc resection or intralesional excision for re-resection has rarely been reported. This study aimed to compare the prognostic value of en bloc resection with that of intralesional excision in patients undergoing re-resection for giant cell tumors of the spine.

Methods: This retrospective analysis evaluated patients who underwent revision surgeries for relapse of giant cell tumors of the spine at our center between January 2005 and January 2021. Local progression-free survival represents the duration between en bloc resection or intralesional excision and tumor recurrence. Neurological recovery, survival rates, local control, and complications were evaluated. The Kaplan–Meier estimator was used for survival analysis.

Results: A total of 22 patients (nine men and 13 women) with a mean age of 34.1 (range 19–63) years were included. Significant statistical differences were found in the local tumor recurrence rate between patients treated with en bloc resection and those treated with intralesional excision (p < 0.05). The 5- and 10-year local progression-free survival rates were both 90% in the en bloc resection group, while in the intralesional excision group, the 5-year local progression-free survival rate was 80% with a 10-year rate of 45.7%. The en bloc resection group had a lower local tumor recurrence rate than that of the intralesional excision group (p < 0.05), but the former had a higher rate of complications (p = 0.015).

Conclusions: This study revealed a low local recurrence rate in patients who underwent en bloc resection for giant cell tumors, while the perioperative complication rate was high.

Keywords

En Bloc Resection / Giant Cell Tumor / Intralesional Excision / Radiotherapy / Recurrence

References

[1] Leggett AR, Berg AR, Hullinger H, Benevenia JB. Diagnosis and treatment of lumbar giant cell tumor of the spine: update on current management strategies. Diagnostics (Basel). 2022;12:857.

[2] Mastboom MJL, Palmerini E, Verspoor FGM, Rueten-Budde AJ, Stacchiotti S, Staals EL, et al. Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study. Lancet Oncol. 2019;20:877–886.

[3] Yuan B, Zhang L, Yang S, Ouyang H, Han S, Jiang L, et al. Imaging features of aggressive giant cell tumors of the mobile spine: retrospective analysis of 101 patients from single center. Glob Spine J. 2022;12:1449–1461.

[4] Ma Y, Li J, Pan J, Yan W, Huang Q, Liu T, et al. Treatment options and prognosis for repeatedly recurrent giant cell tumor of the spine. Eur Spine J. 2016;25:4033–4042.

[5] Junming M, Cheng Y, Dong C, Jianru X, Xinghai Y, Quan H, et al. Giant cell tumor of the cervical spine: a series of 22 cases and outcomes. Spine (Phila Pa 1976). 2008;33:280–288.

[6] Lin P, Lin N, Teng W, Wang SD, Pan WB, Huang X, et al. Recurrence of giant cell tumor of the spine after resection: a report of 10 cases. Orthop Surg. 2018;10:107–114.

[7] Luksanapruksa P, Buchowski JM, Singhatanadgige W, Bumpass DB. Systematic review and meta-analysis of en bloc vertebrectomy compared with intralesional resection for giant cell tumors of the mobile spine. Glob Spine J. 2016;6:798–803.

[8] Boriani S, Bandiera S, Casadei R, Boriani L, Donthineni R, Gasbarrini A, et al. Giant cell tumor of the mobile spine: a review of 49 cases. Spine (Phila Pa 1976). 2012;37:E37–E45.

[9] Jia Q, Chen G, Cao J, Yang X, Zhou Z, Wei H, et al. Clinical features and prognostic factors of pediatric spine giant cell tumors: report of 31 clinical cases in a single center. Spine J. 2019;19:1232–1241.

[10] Elder BD, Sankey EW, Goodwin CR, Kosztowski TA, Lo SFL, Bydon A, et al. Surgical outcomes in patients with high spinal instability neoplasm score secondary to spinal giant cell tumors. Glob Spine J. 2016;6:21–28.

[11] Sciubba DM, De la Garza Ramos RR, Goodwin CR, et al. Total en bloc spondylectomy for locally aggressive and primary malignant tumors of the lumbar spine. Eur Spine J. 2016;25:4080–4087.

[12] Ming Z, Kangwu C, Huilin Y, Genlin W, Jian L, Yiming J, et al. Analysis of risk factors for recurrence of giant cell tumor of the sacrum and mobile spine combined with preoperative embolization. Turk Neurosurg. 2013;23:645–652.

[13] Yokogawa N, Murakami H, Demura S, Kato S, Yoshioka K, Shimizu T, et al. Total spondylectomy for Enneking stage III giant cell tumor of the mobile spine. Eur Spine J. 2018;27:3084–3091.

[14] Luksanapruksa P, Buchowski JM, Singhatanadgige W, Rose PC, Bumpass DB. Management of spinal giant cell tumors. Spine J. 2016;16:259–269.

[15] Xu K, Wan W, Li B, Li J, Huang Q, Liu Y, et al. Prognostic significance of preoperative plasma D-dimer level and clinical factors in patients with spinal giant cell tumor: retrospective analysis of 153 patients in a single center. World Neurosurg. 2019;122:e872–e880.

[16] Li J, Li B, Zhou P, Zhao J, Wu Z, Yang X, et al. Nomograms for prognostic factors of spinal giant cell tumor combining traditional clinical characteristics with inflammatory biomarkers after gross total resection. Oncotarget. 2017;8:86934–86946.

[17] Xu W, Li X, Huang W, Wang Y, Han S, Chen S, et al. Factors affecting prognosis of patients with giant cell tumors of the mobile spine: retrospective analysis of 102 patients in a single center. Ann Surg Oncol. 2013;20:804–810.

[18] Charest-Morin R, Boriani S, Fisher CG, et al. Benign tumors of the spine: has new chemotherapy and interventional radiology changed the treatment paradigm? Spine (Phila Pa 1976). 2016;41(suppl 20):S178–S185.

[19] Zhou H, Liu S, Li Z, Liu X, Dang L, Li Y, et al. 3D-printed vertebral body for anterior spinal reconstruction in patients with thoracolumbar spinal tumors. J Neurosurg Spine. 2022;37:1–9.

[20] Zhou M, Yang H, Chen K, et al. Surgical treatment of giant cell tumors of the sacrum and spine combined with pre-operative transarterial embolization. Oncol Lett. 2013;6:185–190.

[21] Zhou H, Wu F, Dang L, Li Y, Liu X, Liu Z, et al. Comparison of the prognostic factors of total en bloc spondylectomy and total piecemeal spondylectomy in patients with Enneking stage III giant cell tumor in the thoracic and lumbar spine. Eur Spine J. 2023;32:254–260.

RIGHTS & PERMISSIONS

2024 The Authors. Orthopaedic Surgery published by Tianjin Hospital and John Wiley & Sons Australia, Ltd.